Kellanova (K) Stock News

UnitedHealth reported Q3 2026 earnings with strong operational momentum driven by AI integration and enterprise reforms. The company reiterated its 13-16% long-term growth target, highlighting AI-enabled workflow improvements, a 30% reduction in prior authorizations, and strong commercial client retention heading into 2027. Q3 revenue reached $113 billion with adjusted EPS of $4.69.

Travelers reported Q3 2026 core income of $1.95 billion with a 22.1% core return on equity. The insurer is leveraging AI to improve claims operations and pricing, maintaining durable underwriting income across market cycles through scale and pricing discipline. The company grew its investment portfolio by $6 billion while returning record capital to shareholders through dividends and buybacks, positioning it well for continued strong financial performance.

Bank of America reported Q3 2026 adjusted net income of $8.1 billion, with a $1.2 billion regulatory settlement charge. Management raised 2027 net interest income guidance to 8% or more growth, citing accelerating fixed-rate asset repricing. The bank's strong balance sheet, low loan-to-deposit ratio, and deposit growth of $2 trillion provide competitive advantages and margin protection.

Wells Fargo reported Q3 2026 diluted earnings per share increased 13% year-over-year to $1.87. The bank achieved this through relentless efficiency improvements including a 30% headcount reduction from its 2020 peak, strategic hiring of 130+ business bankers that drove credit card openings up 61%, and optimized balance sheet management. Management expects continued progress toward its 17-18% return on tangible common equity target.

Citigroup reported Q3 2026 net income of $5.2 billion, with management executing a structural overhaul that cuts costs through severance-funded headcount reductions while reinvesting in AI and technology. The bank reduced tech vendor spending by 30% year-over-year through internal AI deployment, and wealth management attracted $38 billion in net new investment assets, doubling year-over-year. Revenue expanded 8% as the bank pursues disciplined expense controls and balance sheet allocation toward long-term financial targets.

Rivian's most valuable opportunity may lie in its robotics venture rather than vehicle sales. The company owns approximately one-third of Mind Robotics, an AI-enabled manufacturing technology company founded by Rivian CEO RJ Scaringe. Mind recently hired Doug Field, a veteran executive from Tesla and Ford, as president. With a stake valued at over $1 billion and $1 billion in recent funding, Mind Robotics could provide significant returns for Rivian investors if successful, though Rivian's EV business still needs to achieve profitability.

Chery Auto will demonstrate its purpose-built Level 4 autonomous Robotaxi at its 2026 International User Summit and announce a strategic partnership with UAE-based K2 to support commercial deployment overseas. The vehicle features native autonomous architecture, comprehensive safety systems, and is designed for scalable fleet operations with autonomous daily cycles.

Johnson & Johnson reported strong Q3 results with revenue beating expectations and raised full-year guidance, driven by excellent pharmaceutical segment performance including cancer drug Darzalex and autoimmune treatment Tremfya. However, the medtech division underperformed, particularly due to safety concerns with Impella heart pumps. Despite near-term headwinds, the article argues J&J remains a solid long-term buy given its robust pharmaceutical pipeline, upcoming medtech innovations like robotic surgery devices, and its status as a Dividend King with 64 consecutive years of dividend increases.

A securities fraud class action lawsuit has been filed against AEVEX Corp. (NYSE: AVEX) for allegedly making material misstatements regarding a pre-arranged secondary public offering shortly after its April 2026 IPO. The company failed to disclose that Madison Dearborn Partners planned to waive lock-up restrictions and sell shares, causing the stock to plummet approximately 23% in early June 2026. Investors have until October 20, 2026, to file for lead plaintiff status.

Kratos Defense is betting on military demand for its autonomous Valkyrie aircraft, which has demonstrated its technology. However, the key question for investors is whether the company can convert this validation into sufficient funded production orders to justify its expanding capacity.

Ascendis Pharma announced that the European Medicines Agency's CHMP committee issued a positive opinion for TransCon CNP (Navepegritide), a once-weekly treatment for achondroplasia in children aged 2+ years with open epiphyses. The European Commission is expected to make a final decision in Q4 2026, with market launch in Germany anticipated for Q1 2027 under the brand name YUVIWEL®. The drug was previously approved by the FDA in February 2026.

The article examines the six best-performing Nasdaq-100 stocks in 2026, led by Moderna (up 667%), followed by SanDisk, Micron Technology, Marvell Technology, AMD, and Intel. While these stocks have benefited from AI-driven demand and strong fundamentals, the article cautions that their massive gains may already be priced in, making future performance uncertain. Past performance does not guarantee future results, as illustrated by examples like Novo Nordisk, which surged in 2023 but declined in 2024.

SpaceX is transitioning from a pure space launch company to an AI and telecommunications giant. While the company will reduce launch frequency in 2026-2027 as it retires Falcon 9 rockets, larger Starship vehicles will compensate with greater payload capacity. The real growth opportunity lies in Starlink's expansion into mobile telecommunications, with V3 satellites promising 100x bandwidth increase. SpaceX recently acquired $8 billion in cellular spectrum licenses to become a major U.S. mobile carrier, rivaling Verizon and AT&T.

Medtronic is one year away from achieving Dividend King status with 49 consecutive years of dividend increases. An investor would need approximately 348 shares (costing ~$32,792) to generate $1,000 in annual dividend income at the current 3% yield. The recent MiniMed spinoff positions Medtronic to focus on higher-margin businesses, potentially enabling larger dividend increases and earnings growth of 7-8% in coming years.

Rosen Law Firm is reminding investors who purchased Qfin Holdings securities between March 18, 2026 and August 25, 2026 of an important November 30, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Qfin made false and misleading statements about the resiliency of its business and downplayed the negative impact of regulatory headwinds on its financial results.

AiMOGA Robotics, leveraging Chery's automotive expertise, is launching Mobo, a consumer-grade humanoid robot designed as a family companion. The robot features voice interaction, visual object recognition, schedule reminders, and long-term memory capabilities. Global pre-orders open on October 21, 2026, marking AiMOGA's expansion from commercial applications to residential home environments.

AiMOGA Robotics will launch Mobo, its first humanoid family companion robot designed for general consumers, on October 21, 2026, in Wuhu, Anhui. The robot features voice interaction, visual object recognition, scheduling reminders, and long-term memory to support family communication and daily routines. AiMOGA leverages Chery's automotive expertise and global R&D infrastructure to develop the robot, marking the company's expansion from commercial applications into household robotics.

Johnson & Johnson raised its full-year sales and earnings guidance after beating Q3 estimates, but the stock fell 6% due to disappointing medical device sales. Despite near-term concerns about the MedTech division and a planned DePuy Synthes spinoff, the company's strong oncology business growth (16%+ in Q3) and reliable 64-year dividend streak make it an attractive long-term buy at current valuations.

XRP could reach $3 by 2030, requiring a 125.6% gain from its October 2026 price of $1.33. However, the article argues this would likely be driven by speculation rather than fundamentals. The coin lacks reliable product-market fit, with financial institutions showing limited demand despite Ripple's efforts to position XRP as a bridge currency. New buyer cohorts like ETFs and digital asset treasury companies would need to emerge for significant price appreciation.

AbbVie is positioned as a reliable dividend stock that avoids high-yield trap characteristics. With 54 consecutive years of dividend increases, strong free cash flow generation, fixed-rate debt, and blockbuster drugs Skyrizi and Rinvoq generating over $7.5 billion quarterly, AbbVie maintains Dividend King status regardless of interest rate cycles. The company's robust pipeline of 90 clinical programs provides future revenue stability.

Charles Schwab reported record quarterly net revenue of $7.2 billion and adjusted EPS of $1.69 in Q3 2026. The company highlighted three key drivers: AI-powered developer productivity gains of 25%, record organic inflows of $190 billion in core net new assets, and high-margin secured lending growth with bank lending up 35% year-over-year to $72.3 billion. Management expects positive trends to continue through Q4, positioning the firm for multiyear growth.

BlackRock reported $205 billion in net inflows during Q3 2026, bringing assets under management to $15.5 trillion. The firm is expanding into private credit and AI infrastructure financing, achieving 11% organic base fee growth for nine consecutive quarters above its 5% target. Active ETFs drove record inflows of $22 billion in the quarter, positioning BlackRock to capture market share as institutional clients shift toward private markets and technology-driven portfolio management.

J.B. Hunt outlined plans to raise contractual rates to offset rising operational expenses including driver pay and medical costs. The company is shifting from spot rate adjustments to multiyear contract price increases, investing over $50 million in driver recruitment and capacity building, and seeing strong growth in its Dedicated Contract Services division with 970 trucks sold year-to-date. Long-term shareholder value depends on successfully enforcing higher rates during 2027 contract renewals.

Fastenal reported Q3 2026 earnings with 15.5% sales growth and faster earnings growth, driven by market share gains in large-account contracts. The company is leveraging digital inventory management technology (FMI) and workflow automation to deepen customer relationships while maintaining near-zero headcount growth, demonstrating strong operating leverage and profitability.

U.S. Bancorp reported record Q3 2026 net revenue of $8 billion with expanding operating efficiency. The bank is diversifying fee income through capital markets expansion (targeting 10%+ of revenue), scaling high-yield deposits via strategic partnerships like the Amazon small business credit card ($1.7B in period-end loans), and rebuilding capital to resume stock buybacks. Net interest margin expanded to 2.84%, positioning the bank to benefit from higher reinvestment rates.

Rosen Law Firm announces a securities class action lawsuit against Hims & Hers Health, Inc. for allegedly making false statements about data privacy practices and billing procedures. The lawsuit claims Hims shared consumer health information with third-party advertisers and charged for prescriptions immediately despite promising consultations with medical providers. Investors who purchased HIMS securities between August 4, 2025 and July 29, 2026 may be eligible for compensation. The lead plaintiff deadline is November 2, 2026.

Changan Automobile announced the completion of Letters of Intent (LoIs) with eight companies covering seven European markets at the 2026 Mondial de l'Auto. The company introduced its 'with U' service program and outlined plans for local production, design centers, and partnerships with logistics, financing, and roadside assistance providers to build a sustainable European ecosystem.

Ralph Lauren stock declined 1.57% on October 16, 2026, underperforming the S&P 500's 1.09% loss. Despite a strong monthly gain of 17.41%, the company trades at a premium valuation with a Forward P/E of 20.82 versus its industry average of 16.44. Upcoming earnings are expected to show EPS growth of 11.08% and revenue growth of 5.92%, though the stock holds a Zacks Rank of #3 (Hold). The Textile-Apparel industry ranks in the bottom 18% of sectors.

Equinix (EQIX) closed at $985.98, down 1.03% and outperforming the S&P 500's 1.09% decline. The data center operator is expected to report earnings on October 28, 2026, with projected EPS growth of 6.92% and revenue growth of 10.95% year-over-year. The stock maintains a Zacks Rank #3 (Hold) with a Forward P/E of 22.93, trading at a premium to its industry average of 13.68.

Dynatrace stock fell 4.17% on October 16, 2026, underperforming the S&P 500's 1.09% decline. Despite a 14.15% monthly gain, the company holds a Zacks Rank #4 (Sell) rating with a Forward P/E of 32.64, significantly above its industry average of 14.61. Upcoming earnings are expected to show 11.36% EPS growth and 15.04% revenue growth year-over-year.